AHR ChIP-seq in primary human hepatocytes treated with TCDD

ChIP-seq was done on cryopreserved primary human hepatocyte with vehicle control - 0.1% dimethylsulfide (DMSO), or 1nM 2,3,7,8 tetrachlorodibezno-p-dioxin (TCDD) agonist treatment to identify AHR binding regions throughout the genome. We identified 1,984 binding peaks when comparing TCDD vs. vehicle control Primary human hepatocytes were treated with vehicle control (DMOS) or 1 nM TCDD for 24 hours before cells were collected for ChIP-seq. Sequencing was carried out on Illumina HiSeq 2000